vs
FTI CONSULTING, INC（FCN）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
FTI CONSULTING, INC的季度营收约是Royalty Pharma plc的1.6倍（$983.3M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 5.9%，领先28.6%），FTI CONSULTING, INC同比增速更快（9.5% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 1.8%）
FTI咨询成立于1982年，总部位于美国华盛顿特区，是全球顶尖的金融咨询服务商之一。公司核心业务涵盖企业融资与重组、经济咨询、法务与诉讼咨询、战略传播、科技及战略咨询等领域，在31个国家拥有逾7700名员工。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FCN vs RPRX — 直观对比
营收规模更大
FCN
是对方的1.6倍
$622.0M
营收增速更快
FCN
高出4.7%
4.8%
净利率更高
RPRX
高出28.6%
5.9%
两年增速更快
RPRX
近两年复合增速
1.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $983.3M | $622.0M |
| 净利润 | $57.6M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 8.5% | 62.4% |
| 净利率 | 5.9% | 34.4% |
| 营收同比 | 9.5% | 4.8% |
| 净利润同比 | -6.8% | 2.9% |
| 每股收益（稀释后） | $1.90 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCNRPRX
| Q1 26 | $983.3M | — | ||
| Q4 25 | $990.7M | $622.0M | ||
| Q3 25 | $956.2M | $609.3M | ||
| Q2 25 | $943.7M | $578.7M | ||
| Q1 25 | $898.3M | $568.2M | ||
| Q4 24 | $894.9M | $593.6M | ||
| Q3 24 | $926.0M | $564.7M | ||
| Q2 24 | $949.2M | $537.3M |
净利润FCNRPRX
| Q1 26 | $57.6M | — | ||
| Q4 25 | $54.5M | $214.2M | ||
| Q3 25 | $82.8M | $288.2M | ||
| Q2 25 | $71.7M | $30.2M | ||
| Q1 25 | $61.8M | $238.3M | ||
| Q4 24 | $49.7M | $208.2M | ||
| Q3 24 | $66.5M | $544.0M | ||
| Q2 24 | $83.9M | $102.0M |
毛利率FCNRPRX
| Q1 26 | — | — | ||
| Q4 25 | 31.1% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 32.1% | — | ||
| Q1 25 | 32.2% | — | ||
| Q4 24 | 30.2% | — | ||
| Q3 24 | 32.2% | — | ||
| Q2 24 | 32.8% | — |
营业利润率FCNRPRX
| Q1 26 | 8.5% | — | ||
| Q4 25 | 9.4% | 62.4% | ||
| Q3 25 | 12.3% | 70.1% | ||
| Q2 25 | 10.5% | 36.3% | ||
| Q1 25 | 8.8% | 94.0% | ||
| Q4 24 | 5.9% | 60.9% | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | 11.0% | 50.2% |
净利率FCNRPRX
| Q1 26 | 5.9% | — | ||
| Q4 25 | 5.5% | 34.4% | ||
| Q3 25 | 8.7% | 47.3% | ||
| Q2 25 | 7.6% | 5.2% | ||
| Q1 25 | 6.9% | 41.9% | ||
| Q4 24 | 5.6% | 35.1% | ||
| Q3 24 | 7.2% | 96.3% | ||
| Q2 24 | 8.8% | 19.0% |
每股收益（稀释后）FCNRPRX
| Q1 26 | $1.90 | — | ||
| Q4 25 | $1.77 | $0.49 | ||
| Q3 25 | $2.60 | $0.67 | ||
| Q2 25 | $2.13 | $0.07 | ||
| Q1 25 | $1.74 | $0.55 | ||
| Q4 24 | $1.39 | $0.46 | ||
| Q3 24 | $1.85 | $1.21 | ||
| Q2 24 | $2.34 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.3M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | — | $9.7B |
| 总资产 | $3.5B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FCNRPRX
| Q1 26 | $198.3M | — | ||
| Q4 25 | $265.1M | $618.7M | ||
| Q3 25 | $146.0M | $938.9M | ||
| Q2 25 | $152.8M | $631.9M | ||
| Q1 25 | $151.1M | $1.1B | ||
| Q4 24 | $660.5M | $929.0M | ||
| Q3 24 | $386.3M | $950.1M | ||
| Q2 24 | $226.4M | $1.8B |
总债务FCNRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $0 | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | $60.0M | $7.6B |
股东权益FCNRPRX
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | $9.7B | ||
| Q3 25 | $1.7B | $9.6B | ||
| Q2 25 | $1.9B | $9.5B | ||
| Q1 25 | $2.1B | $9.8B | ||
| Q4 24 | $2.3B | $10.3B | ||
| Q3 24 | $2.3B | $10.3B | ||
| Q2 24 | $2.1B | $9.8B |
总资产FCNRPRX
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | $19.6B | ||
| Q3 25 | $3.5B | $19.3B | ||
| Q2 25 | $3.5B | $18.3B | ||
| Q1 25 | $3.3B | $17.6B | ||
| Q4 24 | $3.6B | $18.2B | ||
| Q3 24 | $3.5B | $18.0B | ||
| Q2 24 | $3.4B | $17.7B |
负债/权益比FCNRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.00× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | 0.03× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-310.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -5.38× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FCNRPRX
| Q1 26 | $-310.0M | — | ||
| Q4 25 | $359.8M | $827.1M | ||
| Q3 25 | $201.9M | $702.6M | ||
| Q2 25 | $55.7M | $364.0M | ||
| Q1 25 | $-465.2M | $596.1M | ||
| Q4 24 | $315.3M | $742.5M | ||
| Q3 24 | $219.4M | $703.6M | ||
| Q2 24 | $135.2M | $658.2M |
自由现金流FCNRPRX
| Q1 26 | — | — | ||
| Q4 25 | $351.4M | — | ||
| Q3 25 | $187.0M | — | ||
| Q2 25 | $38.3M | — | ||
| Q1 25 | $-483.0M | — | ||
| Q4 24 | $301.6M | — | ||
| Q3 24 | $212.3M | — | ||
| Q2 24 | $125.2M | — |
自由现金流率FCNRPRX
| Q1 26 | — | — | ||
| Q4 25 | 35.5% | — | ||
| Q3 25 | 19.6% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | -53.8% | — | ||
| Q4 24 | 33.7% | — | ||
| Q3 24 | 22.9% | — | ||
| Q2 24 | 13.2% | — |
资本支出强度FCNRPRX
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 1.1% | — |
现金转化率FCNRPRX
| Q1 26 | -5.38× | — | ||
| Q4 25 | 6.60× | 3.86× | ||
| Q3 25 | 2.44× | 2.44× | ||
| Q2 25 | 0.78× | 12.06× | ||
| Q1 25 | -7.52× | 2.50× | ||
| Q4 24 | 6.34× | 3.57× | ||
| Q3 24 | 3.30× | 1.29× | ||
| Q2 24 | 1.61× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FCN
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
